Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.97 USD | +6.93% |
|
+9.01% | +15.62% |
Jun. 25 | Oppenheimer Initiates Keros Therapeutics at Outperform With $102 Price Target | MT |
Jun. 18 | Keros Therapeutics Names Chief Executive Officer Jasbir Seehra as Board Chair | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.62% | 1.55B | C- | ||
+20.95% | 127B | B+ | ||
+23.00% | 116B | B+ | ||
+25.15% | 27.69B | B | ||
-19.75% | 19.62B | B+ | ||
-16.57% | 16.26B | A- | ||
-16.56% | 15.49B | B | ||
+11.19% | 14.81B | C+ | ||
-46.65% | 14.39B | A- | ||
+57.74% | 14.11B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KROS Stock
- Ratings Keros Therapeutics, Inc.